TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02278887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Translational research
Description: Before during and at progression/regression biopsies and blood will be taken for translational research

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Translational research
Description: Before during and at progression/regression biopsies and blood will be taken for translational research

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The patient receives 2 days cyclophosphamide via IV to deplete T-cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: The patient receives 5 days fludarabine via IV to deplete T-cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After infusion of the TIL, the patient receives IL-2 to keep the TIL active.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab infusion
Description: In arm A patients will be treated with 4 infusion of ipilimumab
Study: NCT03313310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment Intervention
Description: Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
Study: NCT00607542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: baclofen
Description: 2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
Study: NCT01135836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver
Description: a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline
Description: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: CO2 was removed by passive exsufflation through the port site.
Study: NCT01309243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Description: Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
Study: NCT03626077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy program
Description: this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Link Upper Limb Exerciser
Description: The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: physical therapy program and E-Link Upper Limb Exerciser
Description: physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
Study: NCT00675792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
Study: NCT04481646

Intervention type: DIAGNOSTIC_TEST
Intervention: Face mask sampling
Description: Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.

Intervention type: DIAGNOSTIC_TEST
Intervention: Face mask sampling
Description: Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.

Intervention type: DIAGNOSTIC_TEST
Intervention: Face mask sampling
Description: Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
Study: NCT03239418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham neuromuscular electrical stimulation
Description: Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
Study: NCT01377792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: comparison of different dosages of drug
Study: NCT01840449

Intervention type: DRUG
Intervention: Somatuline Autogel® 60, 90 or 120 mg

Intervention type: DRUG
Intervention: Somatuline Autogel® 60, 90 or 120 mg
Study: NCT01276613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
Study: NCT04563598

Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle intervention (ILI)
Description: Lifestyle intervention focused on weight loss through diet and physical activity

Intervention type: BEHAVIORAL
Intervention: Diabetes support and education (DSE)
Description: Behavioral intervention focused on diabetes support and education
Study: NCT04485299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifluorid 10 ,VOCO
Description: NaF and CaF 10 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride 5% Dental Varnish
Description: 5% NaF
Study: NCT02068859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Cream 8%
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Study: NCT05423431

Intervention type: OTHER
Intervention: Observation
Description: Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
Study: NCT04547621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Intensity-modulated radiotherapy 20Gy/10fx

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Hypofractionated Stereotactic Radiotherapy 30Gy/5fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75 mg/m2 concurrently administered with RT.
Study: NCT00002716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Study: NCT02068859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Gel 1%
Description: Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
Study: NCT01273662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
Study: NCT01250171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 10 mg/kg
Description: Secukinumab was prepared in a sterile water solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab 10 mg/kg
Description: Canakinumab was prepared in a sterile water solution.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution for infusion contained 5% glucose.
Study: NCT00002716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT00002525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: given after surgery at dose of 20mg/m\^2 IV push on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: given after surgery at dose of 20mg/m\^2 IV push on days 1-5
Study: NCT04045990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
Study: NCT02914431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printing Personalized Titanium Plate
Description: The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
Study: NCT03066583

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: trephination with placebo
Description: trephination under US guidance and placebo injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trephination with platelet rich plasma
Description: trephination under US guidance and platelet rich plasma injection
Study: NCT04606667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program
Study: NCT04351477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage chair
Description: Mechanical massage chair
Study: NCT03461302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical coal tar
Description: Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: Clobetasone butyrate 0.05% ointment
Study: NCT01044758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 62.5mg
Description: 62.5mg twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 62.5mg
Description: 62.5mg twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 125mg
Description: 125mg twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 125mg
Description: 125mg twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250mg
Description: 250mg twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250mg
Description: 250mg twice daily (2 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule twice daily (2 weeks)
Study: NCT00944307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg orally once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: raltegravir 400mg orally once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antacid
Description: aluminum, magnesium, simethicone-containing antacid 30mL orally once
Study: NCT02669667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9314
Description: single dose of MEDI9314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo
Study: NCT00002716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT02669667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single dose of placebo
Study: NCT04212754

Intervention type: OTHER
Intervention: Exposure: human development index of country
Description: Primary comparison: Between country groups defined by human development index.
Study: NCT04393792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: 0.23% three times daily (tds) for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% three times daily (tds) for 3 days
Study: NCT01617798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental metolazone diuresis
Description: Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control-- furosemide (lasix) only
Description: Control arm will receive furosemide as monotherapy for diuresis
Study: NCT00551135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 75 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 25 mg BID
Study: NCT03693040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
Study: NCT03171116

Intervention type: OTHER
Intervention: none intervention
Description: it is not an interventional study; it is an observational study

Intervention type: OTHER
Intervention: none intervention
Description: it is not an interventional study; it is an observational study

Intervention type: OTHER
Intervention: none intervention
Description: it is not an interventional study; it is an observational study
Study: NCT03329105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea Salt Mouth Rinse
Description: Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Oral Health Practices
Description: Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Oral Health Practices
Description: Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
Study: NCT00830518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib capsules